Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China · Delayed Price · Currency is CNY 37.07
-1.59 (-4.11%)
Nov 6, 2026, 11:30 AM CST
Hangzhou Biotest Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,424 | 5,528 | 3,452 | 3,229 | 4,928 | 7,456 | |
Market Cap Growth | -9.74% | 60.13% | 6.92% | -34.48% | -33.91% | - |
Enterprise Value | 4,299 | 4,006 | 1,845 | 1,370 | 2,774 | 5,736 |
Last Close Price | 38.66 | 37.09 | 22.31 | 19.84 | 28.18 | 40.88 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 500.04 | 112.24 | 20.36 | 30.29 | 6.37 | 8.94 |
PS Ratio | 12.01 | 12.34 | 6.17 | 7.30 | 2.59 | 4.10 |
PB Ratio | 2.53 | 2.33 | 1.43 | 1.33 | 1.92 | 3.54 |
P/TBV Ratio | 2.91 | 2.63 | 1.62 | 1.46 | 2.10 | 3.57 |
P/FCF Ratio | - | - | - | 43.08 | 9.40 | 10.53 |
P/OCF Ratio | 59.75 | 51.92 | 26.80 | 24.58 | 7.01 | 8.21 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 9.52 | 8.94 | 3.30 | 3.10 | 1.46 | 3.16 |
EV/EBITDA Ratio | 103.51 | 113.84 | 13.77 | 47.44 | 3.59 | 5.92 |
EV/EBIT Ratio | 276.50 | 357.25 | 16.36 | 325.74 | 3.69 | 5.97 |
EV/FCF Ratio | - | - | - | 18.28 | 5.29 | 8.10 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0 | 0 | 0.00 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 2.41 | 0.01 | 0.00 | 0.09 | 0.01 | 0.01 |
Debt / FCF Ratio | - | - | - | 0.04 | 0.02 | 0.02 |
Net Debt / Equity Ratio | -0.52 | -0.63 | -0.70 | -0.79 | -0.79 | -0.81 |
Net Debt / EBITDA Ratio | -27.06 | -42.31 | -12.67 | -66.28 | -2.63 | -1.77 |
Net Debt / FCF Ratio | 23.39 | 63.62 | 14.61 | -25.54 | -3.88 | -2.42 |
Asset Turnover | 0.19 | 0.17 | 0.22 | 0.17 | 0.73 | 1.19 |
Inventory Turnover | 3.40 | 3.46 | 3.32 | 2.30 | 6.79 | 6.03 |
Quick Ratio | 9.87 | 10.02 | 10.08 | 13.27 | 12.16 | 5.93 |
Current Ratio | 10.58 | 10.52 | 10.51 | 13.97 | 13.07 | 6.40 |
Return on Equity (ROE) | 0.40% | 1.97% | 6.90% | 4.23% | 33.13% | 65.52% |
Return on Assets (ROA) | 0.40% | 0.27% | 2.72% | 0.10% | 18.15% | 39.19% |
Return on Invested Capital (ROIC) | 1.56% | 1.33% | 15.80% | 0.74% | 140.06% | 283.49% |
Return on Capital Employed (ROCE) | 0.70% | 0.50% | 4.70% | 0.20% | 29.20% | 45.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.20% | 0.89% | 4.91% | 3.30% | 15.70% | 11.18% |
FCF Yield | -0.89% | -0.42% | -3.37% | 2.32% | 10.64% | 9.50% |
Dividend Yield | 1.89% | 1.30% | 4.68% | 2.63% | 4.76% | 4.29% |
Payout Ratio | 1018.48% | 324.60% | 49.34% | 220.13% | 41.37% | 2.51% |
Buyback Yield / Dilution | 11.30% | 1.72% | 1.23% | 0.10% | -23.14% | -8.33% |
Total Shareholder Return | 13.19% | 3.02% | 5.92% | 2.73% | -18.38% | -4.04% |